Literature DB >> 22962569

Tartrate-Resistant Acid Phosphatase 5b is a Useful Serum Marker for Diagnosis and Recurrence Detection of Giant Cell Tumor of Bone.

Tetsuya Shinozaki1, Kenichi Saito, Tsutomu Kobayashi, Takashi Yanagawa, Kenji Takagishi.   

Abstract

Serum tartrate-resistant acid phosphatase (TRACP) 5b was investigated for use as a marker for diagnosis of giant cell tumor (GCT) of bone and for detection of its recurrence.Four patients with GCT of bone who were initially referred to our hospital were classified as a primary group. Three patients who had local recurrence following curettage were classified as a local recurrence group. Five with no recurrence were classified as a no-recurrence group. Eighteen patients with primary and metastatic malignant bone tumors were also enrolled in the study as a control group. Serum TRACP 5b was measured before the biopsy in all patients and was measured periodically after the operation in patients with GCT of bone. Student t-tests were used for statistical analyses.TRACP 5b was greater than 1500 Um/dL in all primary group patients. Mean TRACP 5b values decreased gradually with post-operative time, showing lower values until local recurrence. The mean value of TRACP 5b of the local recurrence group (753 ± 68.7 mU/dL) was significantly higher than that of the no-recurrence group (340.6 ± 78.3 mU/dL). The mean value of TRACP 5b of the control group (466.9 ± 130.3 mU/dL) was much lower than that of the primary group and markedly lower than that of the local recurrence group. However, no significant difference was found between the no-recurrence group and the control group.Serum TRACP 5b is a useful and convenient marker for diagnosing GCT of bone and for predicting its recurrence.

Entities:  

Keywords:  TRACP 5b.; acid phosphatase; diagnosis; giant cell tumor; serum marker

Year:  2012        PMID: 22962569      PMCID: PMC3434889          DOI: 10.2174/1874325001206010392

Source DB:  PubMed          Journal:  Open Orthop J        ISSN: 1874-3250


  25 in total

Review 1.  Therapeutic targeting of osteoclast function and pathways.

Authors:  Matthew L Broadhead; Jonathan C M Clark; Crispin R Dass; Peter F M Choong; Damian E Myers
Journal:  Expert Opin Ther Targets       Date:  2011-01-05       Impact factor: 6.902

2.  Tartrate-resistant acid phosphatase (TRAP) as a serum marker for bone resorption in breast cancer patients with bone metastases.

Authors:  S Tauchert; A di Liberto; T Cordes; M Thill; D Salehin; M Friedrich
Journal:  Clin Exp Obstet Gynecol       Date:  2009       Impact factor: 0.146

3.  Emphasis on the MR imaging findings of brown tumor: a report of five cases.

Authors:  Won Sun Hong; Mi Sook Sung; Kyung-Ah Chun; Jee-Young Kim; Sun-Won Park; Kee-Haeng Lee; Hyun Wook Lim; Yeon Soo Lim; Won Jong Yoo; Myung Hee Chung
Journal:  Skeletal Radiol       Date:  2010-06-13       Impact factor: 2.199

4.  Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.

Authors:  Naoto Kamiya; Hiroyoshi Suzuki; Masashi Yano; Takumi Endo; Makoto Takano; Atsuhi Komaru; Koji Kawamura; Nobuyuki Sekita; Takashi Imamoto; Tomohiko Ichikawa
Journal:  Urology       Date:  2010-03-05       Impact factor: 2.649

5.  Differential gene expression in classic giant cell tumours of bone: Tenascin C as biological risk factor for local relapses and metastases.

Authors:  Laura Pazzaglia; Amalia Conti; Antonella Chiechi; Chiara Novello; Giovanna Magagnoli; Annalisa Astolfi; Andrea Pession; Tibor Krenacs; Marco Alberghini; Piero Picci; Maria Serena Benassi
Journal:  Histopathology       Date:  2010-07       Impact factor: 5.087

6.  Giant cell tumor of bone: risk factors for recurrence.

Authors:  Frank M Klenke; Doris E Wenger; Carrie Y Inwards; Peter S Rose; Franklin H Sim
Journal:  Clin Orthop Relat Res       Date:  2010-08-13       Impact factor: 4.176

7.  Recurrent giant cell tumor of long bones: analysis of surgical management.

Authors:  Frank M Klenke; Doris E Wenger; Carrie Y Inwards; Peter S Rose; Franklin H Sim
Journal:  Clin Orthop Relat Res       Date:  2010-09-16       Impact factor: 4.176

8.  Giant-cell tumor of bone.

Authors:  M Campanacci; N Baldini; S Boriani; A Sudanese
Journal:  J Bone Joint Surg Am       Date:  1987-01       Impact factor: 5.284

9.  Potential role of tartrate-resistant acid phosphatase 5b (TRACP 5b) as a surrogate marker of late loosening in patients with total hip arthroplasty: a cohort study.

Authors:  Lucia Savarino; Sofia Avnet; Michelina Greco; Armando Giunti; Nicola Baldini
Journal:  J Orthop Res       Date:  2010-07       Impact factor: 3.494

10.  The ultrastructural localization of secretory acid phosphatase in giant cell tumor of bone.

Authors:  E F McCarthy; J A Serrano; H L Wasserkrug; H D Dorfman
Journal:  Clin Orthop Relat Res       Date:  1979-06       Impact factor: 4.176

View more
  4 in total

1.  Retrospective analysis of patients with rare-site and metastatic giant cell tumor.

Authors:  Junling Liu; Han Yang; Rui Sun; Zhijun Yang; Zhihua Zhu
Journal:  Chin J Cancer Res       Date:  2013-10       Impact factor: 5.087

2.  Successful treatment with denosumab in a patient with sacral giant cell tumor of bone refractory to combination therapy with arterial embolization and zoledronic acid: A case report.

Authors:  Shunji Nishimura; Kazuhiko Hashimoto; Akihiro Tan; Yukinobu Yagyu; Masao Akagi
Journal:  Mol Clin Oncol       Date:  2017-01-23

3.  Correlations between bone turnover markers, serum magnesium and bone mass density in postmenopausal osteoporosis.

Authors:  Ovidiu Alexandru Mederle; Melania Balas; Sorin Dumitru Ioanoviciu; Camelia-Vidita Gurban; Anca Tudor; Claudia Borza
Journal:  Clin Interv Aging       Date:  2018-08-03       Impact factor: 4.458

4.  Early evaluation of the therapeutic effect of denosumab on tartrate-resistant acid phosphatase 5b expression in a giant cell tumor of bone: a case report.

Authors:  Naoto Watanabe; Seiichi Matsumoto; Takashi Shimoji; Keisuke Ae; Taisuke Tanizawa; Tabu Gokita; Noriko Motoi; Teruko Ueno; Mitsuru Koizumi
Journal:  BMC Res Notes       Date:  2014-09-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.